Fast Facts – Updates for Prevention & Screenings

Confused about what you should do and when? This session will bring concise guidelines and top need-to-know points on prevention screenings for cervical cancer, breast cancer, colon cancer, STIs, mental health, sleep, intimate partner violence, osteoporosis, contraception, and more! Plus – we will cover vital screenings for special populations, including gender non-conforming, trans-identified, and queer folx.

All “V” Things: Vulva, Vestibule, & Vagina

Let’s expose the truth about all things “V”! From learning the nuts and bolts of a consensual pelvic exam to performing quick and efficient assessments, participants can apply guiding principles to real-life case examples. In this session, audience members will leave with a “V” manual for diagnosing and treating abnormal discharge, pelvic pain, dryness, itch, and skin changes.

Hot & Heavy Topics

Are you a true patient advocate? During this presentation, we will tackle tough conversations around medical providers’ implicit and explicit bias – fatphobia, transphobia, ageism, racism, sexism, ability, and slut-shaming. These behaviors perpetuate systemic discrimination and lead to patient barriers in healthcare. Apart from awareness, this session will discuss examples of actions that medical providers can take immediately to mitigate the effects of implicit bias.

SEX – Inclusive Encounters

Let’s end the STIGMA! Creating a safe space for inclusive conversations around healthy sexuality is essential for empowering patients to voice their needs and smash societal sexual shame. During this session, we will discuss the essentials of taking a sexual history, PrEP counseling, what is sex, what are the types of sex people are having, and biopsychosocial influences to the sexual response cycle. And we can’t forget discussions around optimizing sexual function for desire, arousal, and orgasm. 

The Menopause Playbook (Rx=0.50)

Ready to arm your patients with play-by-play strategies to take on menopause? With the number of menopausal women reaching 1.1 billion worldwide by 2025, medical providers must be prepared to have conversations supporting individuals in perimenopause and beyond. This metamorphosis leads to more than just hot flashes. So, let’s talk about the real symptoms that deserve real conversations. In this session, we will also explore hormonal supportive therapy, non-hormonal medications, and alternative modalities for taking a holistic approach to reframing the menopausal transition.

Treasure the Bones: Osteoporosis & Fracture Prevention Strategies in Men & Women: Part 1 & 2 (Rx=0.75)

This session will introduce a comprehensive approach to the identification of women and men at risk for fracture based on bone densitometry and their 10-year fracture risk using the FRAX calculation. There will be a discussion on who should be screened and then interpretation of results of the bone density and FRAX calculation. There will be discussion of the approach to patients based on whether they are at high or very high risk for fracture. In session part 1, there will be a discussion of the initial workup of patients, non-pharmacologic therapy, and initial therapy of the osteoporotic patient at high risk for fracture with pharmacologic therapy. Treatment of patients at high risk due to therapy such as aromatase inhibitors and androgen deprivation therapy will be discussed. Case studies will be presented for managing osteoporotic patients at high risk for fracture.

The second part of this session will review the approach to patients who are at very high risk for fracture based on their bone density or FRAX calculation. This will include discussion of sequencing of pharmacologic therapy with bone building anabolic agents followed by maintenance with anti-resorptive agents. Current controversies will be discussed including long-term use of bisphosphonates, adverse events including osteonecrosis of the jaw (ONJ) and atypical subtrocanteric femur fractures and drug holidays. Concerns about discontinuation of rank ligand inhibitors and the risk for a rapid increase in vertebral fractures will be discussed.  Case studies will be presented for managing osteoporotic patients at very high risk for fracture.

Menopause Magic: Learn Tricks for the Management of Women at Midlife & Beyond (Rx=0.50)

This session will provide the attendee with an overview of the menopause transition into the post-menopause with an emphasis on symptom management.  There will be an update on guidelines for hormone therapy including issues of long-term use and use after the age of 65. The concept of a window of opportunity for treating women early in the post menopause with less cardiovascular risk than older women will be discussed There will be discussion of FDA approved hormonal and non-hormonal therapy and dietary supplement options for the treatment of hot flashes.  There will be a discussion of the identification and treatment of the genito-urinary syndrome of menopause (GSM).  Case studies will be utilized to provide clinical management decision-making.

Capture Current Cervical Cancer Prevention Guidelines: New Screening & Risk-Based Management

Cervical cancer prevention has changed significantly in recent years with less frequent screening and the addition of HPV testing as a stand-alone test along with the option for the Pap and HPV test together as cotesting.  This session will review the appropriate use of Pap testing, the rationale for HPV testing along with the Pap (co-testing) in women 30 and older and the use of HPV testing as a primary screen (stand-alone test) in women 25 and older by two of the FDA approved HPV tests.  There will be a discussion of the new American Cancer Society Guidelines for screening and a review of the new 2019 ASCCP Risk-Based Management Consensus Guidelines for management of abnormal screening and subsequent follow-up with case studies.  These guidelines are a shift from results-based to risk-based management relative to the risk of an existing CIN 3 (pre-cancer).  

Alphabet Soup: AUB & PALM COEIN for Systematic Diagnosis & Management of Abnormal Uterine Bleeding

Abnormal uterine bleeding (AUB) presents due to both structural and non-structural reasons and AUB is a symptom and not a diagnosis.  This session will review a systematic approach to the identification and classification of AUB, leading to a diagnosis using the Palm-Coein classification system.  This system allows the clinician to assess structural diagnoses including polyps, adenomyosis, leiomyoma, and malignancy.  Non-structural diagnoses include coagulopathy, ovulatory dysfunction, endometrial, iatrogenic, and not yet classified. There will be a review of the appropriate workup and the subsequent options for management of AUB, including both medical and surgical interventions.  This will include symptom management and use of newer GnRh antagonists for heavy menstrual bleeding due to fibroids.  These agents expand the options for management by the NP and PA in practice before referral to gynecology for possible surgical options including myomectomy, endometrial ablation, and hysterectomy.